Remodeling and spacing factor 1 overexpression is associated with poor prognosis in renal cell carcinoma

Oncology Letters

Volumn 15, Issue 3, 2018, Pages 3852-3857

  Zhang, Xiuwei ^a   Xue, Dongwei ^a   Hao, Fengxia ^a   Xie, Lingling ^a   He, Jiani ^a   Gai, Junda ^a   Liu, Yuhui ^a   Xu, Hongtao ^a   Li, Qingchang ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Prognosis; Remodeling and spacing factor 1; Renal cell carcinoma

Indexed keywords

HEPATITIS B VIRUS X PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; EVENT FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RENAL CELL CARCINOMA; RISK FACTOR; SURVIVAL RATE;

EID: 85040837018     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2018.7797     Document Type: Article

References (30)

1. Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet 373: 1119-1132, 2009.
2. Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev 34: 193-205, 2008.
3. Hollingsworth JM, Miller DC, Daignault S and Hollenbeck BK: Five-year survival after surgical treatment for kidney cancer: A population-based competing risk analysis. Cancer 109: 1763-1768, 2007.
4. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67: 913-924, 2015.
5. LeRoy G, Orphanides G, Lane WS and Reinberg D: Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science 282: 1900-1904, 1998.
6. Loyola A, Huang JY, LeRoy G, Hu S, Wang YH, Donnelly RJ, Lane WS, Lee SC and Reinberg D: Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol 23: 6759-6768, 2003.
7. Ho L and Crabtree GR: Chromatin remodelling during development. Nature 463: 474-484, 2010.
8. Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL and Shih IeM: Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol 37: 1169-1175, 2006.
9. Yang YI, Ahn JH, Lee KT, Shih IeM and Choi JH: RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res 74: 2258-2269, 2014.
10. Zhao XC, An P, Wu XY, Zhang LM, Long B, Tian Y, Chi XY and Tong DY: Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1. Tumour Biol 37: 7203-7212, 2016.
11. Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia UD, Chen BJ, Saucedo-Cuevas L, Rodriguez Barrueco R, Llobet-Navas D, et al: Integration of genomic data enables selective discovery of breast cancer drivers. Cell 159: 1461-1475, 2014.
12. Cheng CK, Chow LW, Loo WT, Chan TK and Chan V: The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 65: 8646-8654, 2005.
13. Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, Wang TL, Tsai FJ, Shih IeM and Sheu JJ: Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol 178: 2407-2415, 2011.
14. Zhang X, Fu L, Xue D, Zhang X, Hao F, Xie L, He J, Gai J, Liu Y, Xu H, et al: Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer. Virchows Arch 470: 553-560, 2017.
15. ShihIe M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, et al: Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 102: 14004-14009, 2005.
16. Li Q, Dong Q and Wang E: Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun 420: 6-10, 2012.
17. Li H, Zhang Y, Zhang Y, Bai X, Peng Y and He P: Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker. Tumour Biol 35: 5771-5776, 2014.
18. Xie C, Fu L, Xie L, Liu N and Li Q: Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma. Tumour Biol 35: 7595-7601, 2014.
19. O'Sullivan GC, Tangney M, Casey G, Ambrose M, Houston A and Barry OP: Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. Int J Cancer 121: 1930-1940, 2007.
20. Meng ZW, Pan W, Hong HJ, Chen JZ and Chen YL: Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore) 96: e7891, 2017.
21. Davidson B, Trope' CG, Wang TL and Shih IeM: Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 103: 814-819, 2006.
22. Roberts CW and Orkin SH: The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 4: 133-142, 2004.
23. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL and Shih IeM: Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 69: 1407-1415, 2009.
24. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, et al: Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100: 264-270, 2006.
25. Hennessy BT, Nanjundan M, Cheng KW, Nolden L and Mills GB: Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet 14: 381-383, 2006.
26. Bostner J, Ahnström WM, Fornander T, Skoog L, Nordenskjöld B and Stål O: Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26: 6997-7005, 2007.
27. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Killander D and McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990.
28. Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, et al: N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 15: 1171-1182, 1997.
29. Shamay M, Barak O and Shaul Y: HBXAP, a novel PHD-finger protein, possesses transcription repression activity. Genomics 79: 523-529, 2002.
30. Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, Wang TL and Shih IeM: Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol 229: 559-568, 2013.